Skip to main content

Table 3 Baseline characteristics of users of DPP-4 inhibitors

From: Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus

VariablesSitagliptinVildagliptinTeneligliptinAlogliptinLinagliptinp-value
n = 879n = 253n = 260n = 237n = 180
Age (years, mean ± SE)63.1 ± 0.464.2 ± 0.866 ± 0.863.5 ± 0.867.2 ± 0.90.0002*
Sex (female)317 (36.1%)79 (31.2%)87 (33.5%)72 (30.4%)58 (32.2%)0.3791
Medical History
 Cerebrovascular disease24 (50%)7 (14.6%)7 (14.6%)6 (12.5%)4 (8.3%)0.9963
 Ischemic heart disease74 (8.4%)29 (11.5%)14 (5.4%)29 (12.2%)20 (11.1%)0.038*
 Dyslipidemia95 (10.8%)44 (17.4%)28 (10.8%)27 (11.4%)23 (12.8%)0.0688
 Hypertension78 (8.9%)34 (13.4%)38 (14.6%)26 (11%)34 (18.9%)0.0008*
Medication
 Antidiabetic drug628 (71.4%)154 (60.9%)115 (44.2%)144 (60.8%)91 (50.6%)<.0001*
 Lipid-lowering drug377 (42.9%)115 (45.5%)101 (38.9%)127 (53.6%)76 (42.2%)0.0138*
 Antihypertensive drug513 (58.4%)156 (61.7%)154 (59.2%)157 (66.2%)114 (63.3%)0.2087
 NASID177 (20.1%)44 (17.4%)54 (20.8%)45 (19%)33 (18.3%)0.8433
 Steroid67 (7.6%)21 (8.3%)33 (12.7%)22 (9.3%)22 (12.2%)0.0695
  1. DPP-4 dipeptidyl-peptidase 4, SE standard error, NSAID non-steroidal anti-inflammatory drug
  2. *p < 0.05 (among five DPP-4 inhibitors)